Healthcare Aug 05, 2021 08:12 PM (GMT+8) · EqualOcean
Laimei pharmaceutical announced that Laimei (Hong Kong) Co., Ltd. ("Laimei Hong Kong"), a wholly-owned subsidiary of the company, is the company's overseas innovation technology and high-quality project introduction platform. Laimei Hong Kong signed the subscription agreement with replicor Inc. ("replicor") on August 5, 2021. Lai Mei Hongkong intends to invest $2 million 990 thousand (equivalent to RMB 19 million 321 thousand and 679 yuan) in its own capital to purchase its 230 thousand ordinary shares to Replicor at $13 / share. Meanwhile, the two sides are willing to conduct more extensive cooperation in the commercial development of hepatitis B drug market in China, including establishing branches in China and promoting clinical research in China. Development of hepatitis B drugs, China market and other cooperation matters.